Who can be in this study?
This study will be enrolling patients with FXS who are between 3 and 29 years old.
What does study participation involve?
The medication is an investigational cannabidiol (CBD) that is applied to the upper arms/shoulders twice daily.
Who do I contact if I am interested in learning more about this study?
Contact: Shelley Coughlin at connectfx@childrens.harvard.edu